Brief: Xencor Presents Clinical Results from Phase 1a Study of XmAb564 at EULAR 2023 Congress
30/05/2023 23:18
May 30 (Reuters) - Xencor Inc XNCR.O :
* XENCOR PRESENTS CLINICAL RESULTS FROM PHASE 1A STUDY OF
XMAB®564
AT THE EULAR 2023 CONGRESS
* XENCOR INC - ENGINEERED IL2-FC CYTOKINE IS WELL-TOLERATED
AND
SELECTIVELY EXPANDS REGULATORY T CELLS
* XENCOR INC - ANTICIPATE COMPLETING DOSE ESCALATION IN
PSORIASIS
COHORTS IN EARLY 2024
Source text for Eikon: ID:nBw2dyd3Qa
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates